Iron deficiency anemia therapy market seen reaching $6.92 billion by 2030

The Business Research Company says the iron deficiency anemia therapy market will grow from $4.78 billion in 2025 to $6.92 billion in 2030, driven by rising chronic disease rates, wider screening and broader use of oral and intravenous treatments. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The iron deficiency anemia therapy market is expanding as more patients need treatment for a condition tied to nutrition, absorption problems and chronic disease. - Faster diagnosis and more treatment options are pushing demand for both oral iron and intravenous therapies. - Growth in this market matters because iron deficiency anemia affects red blood cell production and can worsen outcomes for patients with other conditions.

What happened: - The Business Research Company released a 2026 market report on iron deficiency anemia therapy on August 13, 2026. - The report puts the market at $4.78 billion in 2025 and $5.15 billion in 2026. - The report forecasts the market will reach $6.92 billion by 2030. - The projected growth rate is 7.8% from 2025 to 2026 and 7.6% over the forecast period to 2030. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - The report links recent growth to higher prevalence of iron deficiency anemia, rising awareness of anemia management, broader use of hospital-based treatment protocols, greater adoption of oral iron supplements and improved diagnostic screening. - Forecast growth is tied to demand for faster anemia correction, more chronic disease cases, specialty anemia clinics, stronger focus on maternal and pediatric care, and advances in iron formulation technology. - The report expects greater use of intravenous iron therapies, more targeted anemia treatments, patient-specific therapy plans, combined oral and parenteral therapies, and tighter focus on safety and effectiveness. - Iron deficiency anemia therapy aims to restore iron to healthy levels so the body can produce normal red blood cells. - Treatment options range from dietary changes and supplements to medical interventions based on a patient’s needs. - Chronic diseases are a major demand driver because conditions such as obesity, diabetes and heart disease can reduce iron absorption and raise anemia risk. - The UK National Health Service reported in June 2024 that 3,615,330 people registered with general practitioners had non-diabetic hyperglycemia in 2023, up 18% from 3,065,825 in 2022. - In 2025, North America held the largest share of the global market. - The Asia-Pacific region is forecast to grow the fastest in the coming years. - The report highlights new features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspots infographics and updated graphics and tables. - The report offers a free sample at Download the free sample report. - The full report is available at View the full market report.

Between the lines: - The strongest growth signals point to a market shifting from basic supplementation toward more segmented, clinic-based and technology-driven care. - The regional split suggests the most mature demand is in North America, while the biggest upside is in Asia-Pacific as healthcare spending and awareness rise. - The chronic disease link means anemia treatment demand is increasingly tied to broader public health trends, not just iron deficiency alone.

What's next: - The market is likely to keep expanding as more health systems move toward faster correction of anemia and more individualized treatment plans. - Intravenous iron and combination therapies appear positioned to gain more share as treatment protocols evolve. - Growth in maternal and pediatric anemia care may create additional demand over the forecast period.

The bottom line: - Iron deficiency anemia therapy is moving into a higher-growth phase, with rising chronic disease burdens and more advanced treatment options widening the global market.